22 BOSTON WHARF ROAD, BOSTON, MA
CEO Agreement Amendment - Abizer Gaslightwala Salary Increase to $625,000
Reports Second Quarter 2026 Financial Results and Highlights Progress of AKTX-101 Towards Phase 1 and Strategic Collaboration for Its ADC Payload Platform
Annual General Meeting Results - Akari Therapeutics Shareholder Vote
Akari Therapeutics Enters into $10 Million Securities Purchase Agreement
Akari Therapeutics Enters $12 Million Securities Purchase Agreement
Announces ADS Ratio Change
Shareholder Approval at Special General Meeting on March 2, 2026
Announces $5 Million Financing, Including Concurrent Registered Direct Offering and Private Placement Priced At-Market
Q2
Q1
Notice of Late Filing for Quarterly Report
FY 2025
Q3
FY 2024
Effectiveness Notice
Amended Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities Offered under a Shelf Registration
Amended Registration Statement for Securities
Notice of Exempt Offering of Securities
RW
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Schedule 13G - Ownership Report
Post-Effective Amendment to Registration Statement
Amended Registration Statement for Depositary Shares
Correspondence
Submission Upload